Anticholinergic medications consist of a heterogeneous group of drugs that are frequently used in the elderly population [8]. They are used therapeutically to block muscarinic receptors in a wide variety of clinical disorders such as urinary incontinence, irritable bowel syndrome, and Parkinson’s disease. Other classes of drugs such as antihistamines and tricyclic antidepressants have anticholinergic effects not necessarily essential to their therapeutic activity [9, 10]. Drugs with anticholinergic activities are often responsible for peripheral and central side effects. Peripheral side effects include dry mouth, constipation, urinary retention, and bowel construction. Central side effects include impaired concentration, confusion, memory impairment, and falls [11]. These effects are of concern in the elderly because of age-related changes in pharmacokinetics and pharmacodynamics, pre-existing cognitive deficits leading to heightened sensitivity to central adverse effects, as well as polypharmacy posing risks of drug interactions [10, 12–15]. Thus, these anticholinergic agents are considered potentially inappropriate in the elderly population.